Caris Life Sciences (CAI) Receivables - Other (2024 - 2026)

Caris Life Sciences' Receivables - Other history runs 3 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Receivables - Other changed N/A year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (changed N/A YoY), while the FY2025 annual figure was $7.2 million, up 56.52% from the prior year.
• Receivables - Other for Q1 2026 stood at $3.7 million, down from $7.2 million in the prior quarter.
• The five-year high for Receivables - Other was $11.2 million in Q2 2025, with the low at $3.7 million in Q1 2026.
• The 3-year median for Receivables - Other is $7.2 million (2025), against an average of $7.3 million.
• Peak annual rise in Receivables - Other reached 56.52% in 2025, while the deepest fall reached 56.52% in 2025.
• Caris Life Sciences' Receivables - Other stood at $4.6 million in 2024, then surged by 56.52% to $7.2 million in 2025, then sank by 48.61% to $3.7 million in 2026.
• Business Quant data shows CAI's Receivables - Other at $3.7 million in Q1 2026, $7.2 million in Q4 2025, and $9.9 million in Q3 2025.